...
首页> 外文期刊>Journal of neuro-oncology. >Feasibility of dose escalation using intraoperative radiotherapy following resection of large brain metastases compared to postoperative stereotactic radiosurgery
【24h】

Feasibility of dose escalation using intraoperative radiotherapy following resection of large brain metastases compared to postoperative stereotactic radiosurgery

机译:与术后立体定向放射外科相比,使用术中放射治疗使用术中放射治疗剂量升级的可行性

获取原文
获取原文并翻译 | 示例
           

摘要

Background and purpose Post-operative SRS (stereotactic radiosurgery) for large brain metastases is challenged by risks of radiation necrosis that limit SRS dose. Intraoperative radiotherapy (IORT) is a potential alternative, however standard dose recommendations are lacking. Methods and materials Twenty consecutive brain metastases treated with post-operative SRS were retrospectively compared to IORT plans generated for 10-30 Gy in 1 fraction to 0-5 mm by estimating the applicator size and distance from critical organs using pre-operative and post-operative MRI. Additionally, 7 consecutive patients treated with IORT 30 Gy to surface were compared to retrospectively generated SRS plans using the post-operative MRI to 15-20 Gy and 30 Gy in 1 fraction marginal dose. Results For the 20 resection cavities treated with SRS and retrospectively compared to IORT, IORT from 10 to 30Gy resulted in lower or not significantly different doses to the optic apparatus and brainstem. Comparatively for the 7 patients treated with IORT 30 Gy to retrospective SRS plans to standard 15-20 Gy and 30 Gy marginal dose, IORT resulted in significantly lower doses to the optic apparatus and brainstem. At a median follow-up of 6.2 months, 86% of patients treated with surgery and IORT achieved local control and 0% developed radiographic or symptomatic radiation necrosis. Conclusions Critical organ dosimetry for IORT remains generally lower than that achieved with single fraction SRS following resection of large brain metastases. We recommend 30 Gy to surface as the preferred prescription, consistent with the dose recommendation for IORT in glioblastoma used in the ongoing INTRAGO-II phase-III trial. Early clinical outcomes appear promising for surgery and IORT.
机译:用于大脑转移的术后SRS(立体定向放射外科)的背景和目的受限制SRS剂量的辐射坏死风险挑战。术中放射治疗(IORT)是一种潜在的替代方案,但缺乏标准剂量建议。使用术前和从临界器官使用预操作和后施加施用器的尺寸和距离,用术后SRS处理的20-30 GY的IORT计划与术后SRS治疗的二十个连续脑转移。操作MRI。此外,将使用术后MRI的后期MRI至15-20 GY和30GY在1分数边缘剂量中进行测定,将用IORT 30 GY处理的患者与表面处理的患者进行了评估。结果对具有SRS处理的20个切除腔,并回顾性与IORT相比,IORT从10到30Gy导致光学设备和脑干的较低或不显着不同。相比之下,使用IOTT 30 GY治疗的7例患者回顾性SRS计划标准15-20 GY和30 Gy边缘剂量,IORE导致光学设备和脑干的剂量显着降低。在6.2个月的中位随访中,86%的手术和IORT治疗的患者达到局部控制和0%发达的射线照相或症状性辐射坏死。结论IORT的临界器官剂量剂量通常低于在大脑转移中切除后单馏分SRS实现的。我们建议将30 Gy表面作为优选的处方,符合在持续的Intracto-II期 - III期试验中使用的胶质母细胞瘤中的IORE中的剂量推荐。早期的临床结果对于手术和IORE看起来很有希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号